Omalizumab, marketed as Xolair, proved more effective than oral immunotherapy (OIT) in treating multi-food allergies in individuals with severe sensitivities to common food allergens.

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 of ...

New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...

In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results presented Sunday at a meeting of ...

Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods ...

Robert A. Wood, MD, FAAAAI, looks back on the first year of omalizumab’s use for food allergy. Patients often are allergic to multiple foods or to foods that are difficult to avoid. Perspective ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...